Strategic collaboration for drug to treat NASH, obesity and diabetes announced
A conditional and exclusive license agreement to develop and commercialize a drug to treat nonalcoholic…
Although type 1 and type 2 diabetes have a huge impact on millions of people worldwide, there is still no cure for either condition. In diabetes, blood sugar levels are dysregulated. If untreated, high levels of blood sugar cause a range of symptoms that can have severe long-term effects. While treatments nowadays can help diabetics manage their symptoms, patients still face many long-term health complications.
Moreover, estimations suggest that the number of people affected by diabetes is steadily increasing worldwide. As a result, the World Health Organization considers diabetes an epidemic. Read on to gather more information about diabetes and how researchers are working on tackling the disease.
European Biotech Industry Report 2021
This report discusses how the Covid-19 pandemic impacted Europe’s life science industry and covers recent market trends, investments, and collaborations.
Go to Report
A conditional and exclusive license agreement to develop and commercialize a drug to treat nonalcoholic…
French biopharma company Adocia has established a first proof of concept for its AdoShell Islets…
U.S. biopharma company Provention Bio, Inc. has secured a term loan facility of up to…
Diabetes management has progressed leaps and bounds in the last 100 years. Francine Kaufman, Chief…
Enrollment has been completed for a study of a regenerative cell therapy investigational product for…
COUR Pharmaceuticals has published details of a study with the Miller Lab at Northwestern University,…
Arecor Therapeutics plc has bought all of Tetris Pharma Ltd shares adding a key commercial…
New data has been published today (July 7) evidencing findings that could lead to better…
U.S. biotech company Imagine Pharma is showcasing its discovery of Type 1 Diabetes Activated Islet…
Eli Lilly and Company is boosting its manufacturing footprint by investing $2.1 billion in two…
After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide…
Evotec and Sernova are set to join forces to advance a beta cell replacement therapy…